Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Intellia Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the research and clinical development of gene editing therapies for patients with genetically-based diseases.
Website: intelliatx.com



Growth: Good revenue growth rate 61.1%, there is acceleration compared to average historical growth rates 46.1%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -886.4%. On average the margin is decreasing steadily. Gross margin is high, +82.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.17 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -12.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 122.1% higher than minimum and 69.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -39.1x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.2 mln (-0.029% of cap.)

Key Financials (Download financials)

Ticker: NTLA
Share price, USD:  (0.0%)13.95
year average price 11.32  


year start price 9.64 2025-02-13

min close price 6.28 2025-04-08

max close price 27.98 2025-10-20

current price 13.95 2026-02-13
Common stocks: 76 972 000

Dividend Yield:  0.0%
EV / Sales: 10.6x
Margin (EBITDA LTM / Revenue): -886.4%
Fundamental value created in LTM:
Market Cap ($m): 1 074
Net Debt ($m): 21
EV (Enterprise Value): 1 095
Price to Book: 1.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-07fool.com

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

2026-01-28zacks.com

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold

2026-01-28zacks.com

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

2026-01-27reuters.com

US FDA lifts clinical hold on Intellia's nerve disease trail

2026-01-14seekingalpha.com

Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-14zacks.com

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average

2025-11-15fool.com

2 Beaten-Down Stocks to Avoid Right Now

2025-11-08globenewswire.com

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

2025-11-07seekingalpha.com

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

2025-11-02fool.com

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-08 2024-05-09 2023-11-09 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:26:55 2025-08-07 16:06:00 2025-02-27 16:03:58 2024-11-07 16:05:30 2024-08-08 16:06:13 2024-05-09 16:25:24 2024-02-22 16:02:42 2023-11-09 16:05:36 2023-08-03 16:13:53 2023-05-04 16:12:48 2023-02-23 16:07:39 2022-11-03 16:03:31 2022-02-24 16:22:35 2021-02-25 18:10:26
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 14M 14M 58M 9M 7M 29M 36M 12M 14M 13M 52M 13M 33M 58M
costOfRevenue 79M 0 10M 0 3M 3M 9M 2M 0 0 8M 0 7M 150M
grossProfit -65M 14M 48M 9M 4M 26M 27M 10M 14M 13M 45M 13M 26M -92M
grossProfitRatio -4.728 1 1 0.626 0.913 0.809 1 1 1
researchAndDevelopmentExpenses 95M 97M 466M 123M 112M 109M 435M 114M 115M 97M 420M 97M 230M 150M
generalAndAdministrativeExpenses 31M 27M 126M 31M 32M 31M 116M 29M 31M 27M 90M 22M 71M 44M
sellingAndMarketingExpenses 16M 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 46M 27M 126M 31M 32M 31M 116M 29M 31M 27M 90M 22M 71M 44M
otherExpenses -95M 0 -10M 0 -114M 0 -9M 0 0 0 -8M 0 -7M -150M
operatingExpenses 46M 124M 582M 154M 143M 140M 543M 143M 146M 125M 503M 119M 294M 44M
costAndExpenses 125M 124M 592M 154M 146M 143M 552M 143M 146M 125M 510M 119M 301M 195M
interestIncome 7M 7M 48M 12M 12M 13M 50M 13M 13M 12M 9M 2M 1M 2M
interestExpense 0 0 0 0 0 0 0 0 0 -9M 0 2M 0 0
depreciationAndAmortization 5M 2M 10M 3M 3M 3M 9M 2M 2M 100 000 8M 10M 7M 6M
ebitda -96M -108M -524M -142M -136M -111M -506M -131M -132M -112M -451M -96M -261M -130M
ebitdaratio -6.994 -7.548 -15.603 -19.612 -3.853 -10.933 -9.735 -8.873 -7.219
operatingIncome -111M -110M -534M -145M -139M -114M -515M -131M -132M -112M -458M -106M -268M -137M
operatingIncomeRatio -8.089 -7.722 -15.89 -19.986 -3.94 -10.933 -9.735 -8.881 -7.955
totalOtherIncomeExpensesNet 10M 9M 15M 9M -8M 7M 34M -4M -4M 9M -16M -8M -42 000 2M
incomeBeforeTax -101M -101M -519M -136M -147M -107M -481M -122M -124M -103M -474M -113M -268M -134M
incomeBeforeTaxRatio -7.352 -7.108 -14.895 -21.126 -3.713 -10.192 -9.098 -8.181 -8.535
incomeTaxExpense 0 0 0 0 0 2M 0 -15M -15M -11M 0 -2M 0 0
netIncome -101M -101M -519M -136M -147M -107M -481M -122M -124M -92M -474M -111M -268M -134M
netIncomeRatio -7.352 -7.108 -14.895 -21.126 -3.713 -10.192 -9.098 -7.325 -8.389
eps -0.92 -0.98 -5.25 -1.34 -1.52 -1.12 -5.42 -1.38 -1.4 -1.05 -6.16 -1.46 -3.78 -2.4
epsdiluted -0.92 -0.98 -1.34 -1.52 -1.12 -1.38 -1.4 -1.05 -1.46
weightedAverageShsOut 110M 104M 99M 101M 97M 96M 89M 89M 88M 88M 77M 76M 71M 56M
weightedAverageShsOutDil 110M 104M 99M 101M 97M 96M 89M 89M 88M 88M 77M 76M 71M 56M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-22 2023-02-23 2022-02-24 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 48M 50M 9M 1M 2M
ebit -534M -515M -458M -268M -137M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -519M -481M -474M -268M -134M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -519M -481M -474M -268M -134M
epsDiluted -5.25 -5.42 -6.16 -3.78 -2.4

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-08 2024-05-09 2023-11-09 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:26:55 2025-08-07 16:06:00 2025-02-27 16:03:58 2024-11-07 16:05:30 2024-08-08 16:06:13 2024-05-09 16:25:24 2024-02-22 16:02:42 2023-11-09 16:05:36 2023-08-03 16:13:53 2023-05-04 16:12:48 2023-02-23 16:07:39 2022-11-03 16:03:31 2022-02-24 16:22:35 2021-02-25 18:10:26
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 193M 156M 189M 120M 131M 172M 227M 168M 172M 294M 524M 141M 123M 160M
shortTermInvestments 318M 303M 412M 538M 560M 619M 685M 687M 736M 639M 669M 687M 625M 437M
cashAndShortTermInvestments 511M 460M 602M 658M 691M 791M 912M 993M 1 072M 1 159M 1 193M 828M 749M 597M
netReceivables 11M 11M 9M 9M 12M 36M 36M 6M 5M 5M 4M 4M 2M 2M
inventory 0 0 0 0 0 1 0 -138M -164M -225M 0 0 0 0
otherCurrentAssets 60M 25M 30M 44M 54M 56M 50M 32M 26M 25M 20M 27M 0 0
totalCurrentAssets 582M 496M 640M 711M 757M 884M 998M 893M 940M 964M 1 217M 859M 769M 617M
propertyPlantEquipmentNet 138M 189M 247M 129M 136M 142M 148M 153M 157M 160M 161M 128M 100M 55M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 188M 197M 44M 47M 262M 176M 155M 197M 41M 294M 142M 98M 425M 5M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 17M 17M 260M 287M 36M 57M 0 0 186M 0 0 0 0 0
totalNonCurrentAssets 343M 403M 551M 462M 434M 376M 303M 350M 384M 454M 303M 226M 525M 60M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 925M 899M 1 191M 1 173M 1 192M 1 260M 1 301M 1 243M 1 323M 1 418M 1 520M 1 084M 1 294M 676M
accountPayables 13M 10M 15M 13M 19M 14M 7M 4M 12M 7M 5M 4M 10M 10M
shortTermDebt 27M 27M 0 19M 38M 19M 0 17M 17M 16M 0 14M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 17M 21M 22M 22M 22M 22M 13M 22M 35M 44M 55M 64M 23M
otherCurrentLiabilities 53M 42M 55M 51M 26M 43M 7M 58M 50M 45M 22M 58M 20M 11M
totalCurrentLiabilities 94M 95M 111M 106M 105M 98M 115M 92M 100M 103M 127M 131M 126M 64M
longTermDebt 71M 76M 0 82M 87M 92M 0 101M 106M 110M 0 84M 0 0
deferredRevenueNonCurrent 0 13M 18M 23M 28M 33M 39M 13M 13M 14M 20M 26M 63M 51M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 -33M -39M -13M 0 0 0 0 0 0
otherNonCurrentLiabilities 13M 0 0 0 0 33M 39M 13M 0 0 24M 56M 0 0
totalNonCurrentLiabilities 83M 88M 208M 105M 115M 126M 136M 114M 119M 124M 158M 128M 128M 85M
otherLiabilities 0 0 0 0 1 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 98M 103M 210M 102M 106M 92M 115M 118M 122M 126M 131M 98M 74M 39M
totalLiabilities 177M 184M 319M 211M 220M 223M 251M 206M 218M 227M 285M 260M 254M 149M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 12 000 10000 10000 10000 10000 10000 9000 9000 9000 9000 9000 8000 7000 7000
retainedEarnings -2 494M -2 393M -2 177M -2 049M -1 913M -1 766M -1 658M -1 526M -1 404M -1 280M -1 177M -1 064M -703M -435M
accumulatedOtherComprehensiveIncomeLoss 989 999 653 000 605 000 3M -1M -947 000 -2M -4M -4M -3M -7M -9M -3M 1000
othertotalStockholdersEquity 3 242M 3 108M 3 008M 2 885M 2 803M 2 567M 2 513M 2 474M 1 898M
totalStockholdersEquity 748M 715M 872M 963M 971M 1 036M 1 050M 1 037M 1 105M 1 191M 1 236M 825M 1 040M 527M
totalEquity 748M 715M 872M 963M 971M 1 036M 1 050M 1 037M 1 105M 1 191M 1 236M 825M 1 040M 527M
totalLiabilitiesAndStockholdersEquity 925M 899M 1 173M 1 192M 1 260M 1 243M 1 323M 1 418M 1 084M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 925M 899M 1 191M 1 173M 1 192M 1 260M 1 301M 1 243M 1 323M 1 418M 1 520M 1 084M 1 294M 676M
totalInvestments 506M 500M 457M 584M 823M 795M 840M 729M 777M 680M 811M 785M 1 050M 442M
totalDebt 98M 103M 210M 102M 106M 111M 115M 118M 122M 126M 131M 98M 74M 39M
netDebt -95M -54M 21M -19M -25M -61M -111M -50M -49M -168M -393M -44M -49M -121M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-22 2023-02-23 2022-02-24 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 9M 36M 4M 2M 2M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 19M 17M
totalPayables 15M 7M 5M 10M 10M
otherPayables 0 0 0 0 0
accruedExpenses 0 60M 39M 23M 15M
capitalLeaseObligationsCurrent 20M 19M 17M 9M 6M
capitalLeaseObligationsNonCurrent 190M 97M 114M 65M 34M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 3 049M 2 711M 2 420M 1 746M 962M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA NTLA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-08 2024-05-09 2023-11-09 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:26:55 2025-08-07 16:06:00 2025-02-27 16:03:58 2024-11-07 16:05:30 2024-08-08 16:06:13 2024-05-09 16:25:24 2024-02-22 16:02:42 2023-11-09 16:05:36 2023-08-03 16:13:53 2023-05-04 16:12:48 2023-02-23 16:07:39 2022-11-03 16:03:31 2022-02-24 16:22:35 2021-02-25 18:10:26
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -101M -101M -519M -136M -147M -107M -481M -122M -124M -103M -474M -113M -268M -134M
depreciationAndAmortization 5M 2M 10M 3M 3M 3M 9M 2M 2M 2M 8M 2M 7M 6M
deferredIncomeTax 0 0 0 0 0 0 0 -4M -3M 0 0 0 9M 0
stockBasedCompensation 20M 22M 154M 40M 41M 34M 134M 35M 36M 27M 91M 25M 47M 20M
changeInWorkingCapital 4M -20M 12M 103 000 30M -30M -52M -14M -5M -37M -54M -6M -23M 58M
accountsReceivables 303 000 -849 000 28M 3M 24M 29 000 -33M -1M -151 000 -1M -2M -1M 99 000 2M
inventory 0 0 0 0 0 0 0 4M 4M 0 0 0 8M 0
accountsPayables 3M -3M 7M -6M 5M 6M 3M -8M 5M 1M -5M -2M 529 000 5M
otherWorkingCapital 647 000 -16M -23M 2M 178 000 -35M -22M -9M -14M -37M -48M -3M -31M 50M
otherNonCashItems -5M -3M -6M 9M 32M 13M -3M 968 000 3M 1M 96M 13M 3M 573 000
netCashProvidedByOperatingActivities -77M -100M -349M -85M -58M -121M -394M -101M -90M -109M -333M -79M -225M -50M
investmentsInPropertyPlantAndEquipment -29 000 -239 000 -6M -1M -1M -3M -14M -4M -4M -4M -58M -4M -13M -4M
acquisitionsNet 0 0 0 0 0 0 0 -84M 0 0 -45M 0 -3M 0
purchasesOfInvestments -117M -56M -936M -206M -301M -260M -904M -129M -243M -382M -429M -161M -1 021M -474M
salesMaturitiesOfInvestments 116M 163M 1 067M 179M 278M 268M 887M 213M 213M 264M 648M 213M 486M 263M
otherInvestingActivites 0 0 21M -23M 8M 84M 0 0 150 000
netCashUsedForInvestingActivites -741 000 107M -8M -24M 6M 80M -35M -122M 48M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 115M 13M 80M 38M 60M 15M 0 1M 23M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 97 000 1M 2M 3M 60M 4M 3M 755 000 722 000
netCashUsedProvidedByFinancingActivities 115M 15M 82M 41M 60M 19M 3M 2M 24M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 122M 0 0 0 0 0
netChangeInCash 37M 22M -38M 3M -41M -55M -295M -3M -122M -229M 410M -7M -39M 107M
cashAtEndOfPeriod 207M 170M 203M 134M 131M 172M 240M 181M 184M 306M 535M 150M 125M 165M
cashAtBeginningOfPeriod 170M 148M 240M 131M 172M 227M 535M 184M 306M 535M 125M 157M 165M 57M
operatingCashFlow -77M -100M -349M -85M -58M -121M -394M -101M -90M -109M -333M -79M -225M -50M
capitalExpenditure -29 000 -239 000 -6M -1M -1M -3M -14M -4M -4M -4M -58M -4M -13M -4M
freeCashFlow -77M -100M -355M -86M -59M -123M -408M -106M -95M -113M -392M -83M -238M -53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-22 2023-02-23 2022-02-24 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 45M 0 0
netCashProvidedByInvestingActivities 126M -31M 160M -551M -214M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 177M 120M 566M 694M 359M
netCommonStockIssuance 177M 120M 566M 694M 359M
commonStockIssuance 177M 120M 566M 694M 359M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 9M 11M 17M 43M 13M
netCashProvidedByFinancingActivities 186M 130M 583M 737M 372M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-27 08:19 ET
Intellia Therapeutics published news for 2025 q4
SEC form 8
2026-01-27 08:19 ET
Intellia Therapeutics published news for 2025 q4
SEC form 8
2026-01-09 08:07 ET
Intellia Therapeutics published news for 2025 q4
SEC form 8
2026-01-09 08:07 ET
Intellia Therapeutics published news for 2025 q4
SEC form 8
2025-11-10 17:24 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-11-10 17:24 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-11-10 17:24 ET
Intellia Therapeutics published news for 2025 q3
SEC form 10
2025-11-06 16:26 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:06 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:06 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-10-27 12:01 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-10-27 12:01 ET
Intellia Therapeutics published news for 2025 q3
SEC form 8
2025-09-25 20:19 ET
Intellia Therapeutics published news for 2025 q2
SEC form 8
2025-09-25 20:19 ET
Intellia Therapeutics published news for 2025 q2
SEC form 10
2025-08-07 20:06 ET
Intellia Therapeutics published news for 2025 q2
SEC form 8
2025-08-07 11:45 ET
Intellia Therapeutics published news for 2025 q2
SEC form 8
2025-08-07 11:45 ET
Intellia Therapeutics published news for 2025 q2
SEC form 8
2025-06-16 11:00 ET
Intellia Therapeutics published news for 2025 q1
SEC form 8
2025-06-16 11:00 ET
Intellia Therapeutics published news for 2025 q1
SEC form 8
2025-05-19 10:21 ET
Intellia Therapeutics published news for 2025 q1
SEC form 8
2025-05-19 10:21 ET
Intellia Therapeutics published news for 2025 q1
SEC form 10
2025-05-08 20:05 ET
Intellia Therapeutics reported for 2025 q1
SEC form 8
2025-05-08 11:45 ET
Intellia Therapeutics published news for 2025 q1
SEC form 8
2025-05-08 11:45 ET
Intellia Therapeutics published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Intellia Therapeutics reported for 2025 q1
SEC form 8
2025-04-07 10:05 ET
Intellia Therapeutics published news for 2025 q1
SEC form 8
2025-04-07 10:05 ET
Intellia Therapeutics published news for 2025 q1
SEC form 10
2025-02-27 16:03 ET
Intellia Therapeutics reported for 2024 q4
SEC form 8
2025-02-27 07:45 ET
Intellia Therapeutics published news for 2024 q4
SEC form 8
2025-02-27 07:45 ET
Intellia Therapeutics published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Intellia Therapeutics reported for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Intellia Therapeutics published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Intellia Therapeutics published news for 2024 q4
SEC form 10
2024-11-07 16:05 ET
Intellia Therapeutics published news for 2024 q3
SEC form 8
2024-11-07 07:45 ET
Intellia Therapeutics published news for 2024 q3
SEC form 8
2024-11-07 07:45 ET
Intellia Therapeutics published news for 2024 q3
SEC form 10
2024-08-08 16:06 ET
Intellia Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 07:45 ET
Intellia Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 07:45 ET
Intellia Therapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Intellia Therapeutics published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Intellia Therapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Intellia Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Intellia Therapeutics published news for 2024 q1
SEC form 10
2024-02-22 16:02 ET
Intellia Therapeutics reported for 2023 q4
SEC form 8
2024-02-22 07:45 ET
Intellia Therapeutics published news for 2023 q4
SEC form 8
2024-02-22 07:45 ET
Intellia Therapeutics published news for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Intellia Therapeutics reported for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Intellia Therapeutics published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Intellia Therapeutics published news for 2023 q4
SEC form 10
2023-11-09 16:05 ET
Intellia Therapeutics published news for 2023 q3
SEC form 8
2023-11-09 07:45 ET
Intellia Therapeutics published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Intellia Therapeutics published news for 2023 q3
SEC form 10
2023-08-03 16:13 ET
Intellia Therapeutics published news for 2023 q2
SEC form 6
2023-08-03 07:45 ET
Intellia Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Intellia Therapeutics published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Intellia Therapeutics reported for 2023 q2
SEC form 6
2023-06-16 16:13 ET
Intellia Therapeutics published news for 2023 q1
SEC form 6
2023-06-12 07:00 ET
Intellia Therapeutics published news for 2023 q1
SEC form 6
2023-06-05 16:52 ET
Intellia Therapeutics published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Intellia Therapeutics reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Intellia Therapeutics reported for 2023 q1
SEC form 6
2023-03-24 07:00 ET
Intellia Therapeutics published news for 2022 q4
SEC form 6
2023-03-02 07:30 ET
Intellia Therapeutics published news for 2022 q4
SEC form 10
2023-02-23 16:07 ET
Intellia Therapeutics reported for 2022 q4
SEC form 6
2023-02-23 07:40 ET
Intellia Therapeutics reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Intellia Therapeutics reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Intellia Therapeutics reported for 2022 q4
SEC form 6
2023-01-05 07:42 ET
Intellia Therapeutics published news for 2022 q4
SEC form 8
2023-01-05 00:00 ET
Intellia Therapeutics published news for 2022 q4
SEC form 6
2022-12-01 17:22 ET
Intellia Therapeutics published news for 2022 q3
SEC form 6
2022-11-14 07:30 ET
Intellia Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 16:42 ET
Intellia Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 16:03 ET
Intellia Therapeutics published news for 2022 q3
SEC form 6
2022-11-03 07:40 ET
Intellia Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Intellia Therapeutics published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Intellia Therapeutics reported for 2022 q3
SEC form 6
2022-09-16 07:36 ET
Intellia Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 16:04 ET
Intellia Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 07:46 ET
Intellia Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Intellia Therapeutics published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Intellia Therapeutics reported for 2022 q2
SEC form 6
2022-06-24 07:46 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-06-16 18:46 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-06-16 18:40 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-06-16 18:36 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-06-16 18:26 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-06-16 18:22 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-06-15 17:01 ET
Intellia Therapeutics published news for 2022 q1
SEC form 10
2022-05-05 16:06 ET
Intellia Therapeutics reported for 2022 q1
SEC form 6
2022-05-05 07:40 ET
Intellia Therapeutics published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Intellia Therapeutics reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Intellia Therapeutics reported for 2022 q1
SEC form 6
2022-05-03 07:00 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-05-02 16:31 ET
Intellia Therapeutics published news for 2022 q1
SEC form 6
2022-03-07 19:15 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 21:07 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 17:15 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 16:01 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-03-03 20:03 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-03-03 19:38 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-03-03 19:34 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:23 ET
Intellia Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 16:22 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 07:46 ET
Intellia Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Intellia Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-02-03 07:45 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2022-01-06 07:51 ET
Intellia Therapeutics published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
Intellia Therapeutics published news for 2021 q4
SEC form 6
2021-12-29 16:20 ET
Intellia Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 16:32 ET
Intellia Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 07:41 ET
Intellia Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Intellia Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Intellia Therapeutics published news for 2021 q3
SEC form 6
2021-10-07 17:41 ET
Intellia Therapeutics published news for 2021 q3
SEC form 6
2021-09-23 17:48 ET
Intellia Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 16:47 ET
Intellia Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 07:45 ET
Intellia Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Intellia Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Intellia Therapeutics published news for 2021 q2
SEC form 6
2021-07-06 16:42 ET
Intellia Therapeutics published news for 2021 q2
SEC form 6
2021-07-02 16:01 ET
Intellia Therapeutics published news for 2021 q2
SEC form 6
2021-06-29 09:48 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 07:00 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-06-24 17:20 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-06-22 07:15 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-06-17 16:15 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-06-15 09:51 ET
Intellia Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 16:06 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 07:45 ET
Intellia Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Intellia Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-04-30 20:55 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 19:51 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:39 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-04-13 16:35 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-04-12 07:45 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-04-07 14:14 ET
Intellia Therapeutics published news for 2021 q1
SEC form 6
2021-03-01 13:59 ET
Intellia Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 18:10 ET
Intellia Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 07:42 ET
Intellia Therapeutics published news for 2020 q4
SEC form 6
2021-01-07 07:46 ET
Intellia Therapeutics published news for 2020 q4
SEC form 6
2020-12-02 16:59 ET
Intellia Therapeutics published news for 2020 q3
SEC form 6
2020-11-09 07:54 ET
Intellia Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 09:01 ET
Intellia Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 07:56 ET
Intellia Therapeutics published news for 2020 q3
SEC form 6
2020-10-19 08:05 ET
Intellia Therapeutics published news for 2020 q3
SEC form 6
2020-10-05 07:45 ET
Intellia Therapeutics published news for 2020 q3